Abstract
Antisense RNA has proven a potent inhibitor of gene expression and has the potential to inhibit retroviral replication at a number of stages in the virus life cycle by targeting both viral and cellular RNA sequences. Antisense RNA complementary to three target regions in the 5′ leader/LTR of human immunodeficiency virus type-1 (HIV-1), the TAR region, the primer binding site and the splice donor (SD)-packaging signal (ψ) region were stably expressed from the CMV IE promoter in Jurkat cells, and expression confirmed by RT-PCR. When challenged with HIV-1, cell lines expressing antisense RNA targeting the SD/ψ region showed significant inhibition of replication (at up to 106 TCID 50/ml). These sequences were also expressed in lymphocytes after transduction using recombinant retroviruses and one sequence complementary to the SD/ψ region inhibited replication of HIV-1. A co-transfection assay using COS-1 cells was also developed both to confirm the antiviral potential of these sequences, and to determine the predominant site of action of these molecules. Antisense RNAs targeting the ψ region and one sequence complementary to the TAR region inhibited expression of viral protein; furthermore, analyses of relative levels of cellular and virion RNA from these assays suggest each of these antisense molecules exerts its effect at an early stage in the transcription–translation pathway, while the longer of the sequences also inhibited packaging of virion RNA. These results suggest that the packaging signal (ψ) of HIV-1 represents an attractive target for antisense RNA-based gene therapy, although the main mode of action of such molecules may well be through antisense effects at an earlier stage of replication than packaging.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout







Similar content being viewed by others
References
Lever AML . Gene therapy for HIV infection. In: Goodfellow P, Lever AML (eds) British Medical Bulletin vol. 51: 1995 pp 149–166
Morgan RA . Gene therapy for HIV infection Clin Exp Immunol 1997 1: 41–44
Berkhout B . Structure and function of the human immunodeficiency virus leader RNA Prog Nucl Acid Res Mol Biol 1996 54: 1–34
Harrison GP et al. Functional analysis of the core packaging signal in a permissive cell line J Virol 1998 72: 5886–5896
McBride MS, Panganiban AT . The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures J Virol 1996 70: 2963–2973
Wei P et al. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA Cell 1998 92: 451–462
Das AT, Klaver B, Berkhout B . Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys) J Virol 1995 69: 3090–3097
Kaye JF, Lever AML . Trans-acting proteins involved in RNA encapsidation and viral assembly in human immunodeficiency virus type 1 J Virol 1996 70: 880–886
Khan R, Giedroc DP . Recombinant human immunodeficiency virus type 1 nucleocapsid (NCp7) protein unwinds tRNA J Biol Chem 1992 267: 6689–6695
Chatterjee S, Johnson PR, Wong KK Jr . Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector Science 1992 258: 1485–1488
Joshi S et al. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression J Virol 1991 65: 5524–5530
Sczakiel G, Pawlita M . Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA J Virol 1991 65: 468–472
Sun LQ et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs Proc Natl Acad Sci USA 1995 92: 7272–7276
Veres G et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication J Virol 1998 72: 1894–1901
Morgenstern JP, Land H . Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line Nucleic Acids Res 1990 18: 3587–3596
Cosset FL et al. High-titer packaging cells producing recombinant retroviruses resistant to human serum J Virol 1995 69: 7430–7436
Veres G et al. Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type-1 gag gene inhibits viral replication in human CD4(+) lymphocytes J Virol 1996 70: 8792–8800
Peng H et al. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector Virology 1996 220: 377–389
Vandendriessche T et al. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes J Virol 1995 69: 4045–4052
Donahue RE et al. Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes Nature Med 1998 4: 181–186
Walker RE . A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins Hum Gene Ther 1996 7: 367–400
Riddell SR et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Nature Med 1996 2: 216–223
Weintraub HM . Antisense RNA and DNA. Molecules that bind with specific messenger RNA's can selectively turn off genes. Eventually certain diseases may be treated with them; today antisense molecules are valuable research tools Sci Am 1990 262: 34–40
Zeffman A et al. The major HIV-1 packaging signal is an extended bulged stem loop whose structure is altered on interaction with the Gag polyprotein J Mol Biol 2000 297: 877–893
Ausubel FM et al. Current Protocols in Molecular Biology Wiley-Interscience: New York 1991
Steffens DL, Gross RW . Sequencing of cloned DNA using bacteriophage lambda gt11 templates Biotechniques 1989 7: 674–680
Richardson JH et al. Helper virus-free transfer of human immunodeficiency virus type 1 vectors J Gen Virol 76: 691–696
Acknowledgements
This work was supported by a MRC Clinical Training Fellowship (DC): G84/4391 and the Sykes Trust.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chadwick, D., Lever, A. Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther 7, 1362–1368 (2000). https://doi.org/10.1038/sj.gt.3301254
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.gt.3301254
Keywords
This article is cited by
-
Antisense oligonucleotides: recent progress in the treatment of various diseases
Beni-Suef University Journal of Basic and Applied Sciences (2022)
-
Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro
Archives of Virology (2009)